Apr 19, 2024
Rhodococcus infections are uncommon, however they can cause serious disease in certain patients. There are a number of challenges though when dealing with Rhodococcus infections, including the fact that much of what we know around their susceptibility profiles and the clinical management of infected individuals actually...
Apr 5, 2024
Phage therapy has gained a lot of traction but the challenges created by this approach have not been properly assessed at a big scale. We often read about therapy successes on isolated cases but, rarely, we read or hear about failures. AAC recently published a case series of patients who failed phage therapy. Today, we...
Feb 23, 2024
The protozoan Lophomonas has been reported to be a pathogen of
humans in a large number of case reports and case series. Most of
these case reports describe infections of the respiratory tract.
Editors in Conversation is joined by two experts to discuss this
possible parasite.
Some of the questions addressed...
Feb 9, 2024
Tuberculosis is one of the most deadly infectious diseases that still causes significant burden of disease, particularly in the developing world. The emergence of resistance to first line agents severely limits the therapeutic options and threaten the ability to control dissemination of this disease. Fortunately,...
Jan 13, 2024
A new generation of B-lactamase inhibitors is likely to reach the market in the upcoming year. These broad-spectrum inhibitors exhibit activity against the most feared class B metallo-B-lactamases maintaining the inhibition of other enzymes. Recently AAC has published three papers that describe the mechanistic bases of...